Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI

Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Boston, USA.
International clinical psychopharmacology (Impact Factor: 2.46). 07/2011; 26(4):206-12. DOI: 10.1097/YIC.0b013e328343ba08
Source: PubMed


To assess whether early changes in Hamilton Depression Rating Scale-17 anxiety/somatization items predict remission in two controlled studies of Hypericum perforatum (St John's wort) versus selective serotonin reuptake inhibitors for major depressive disorder. The Hypericum Depression Trial Study Group (National Institute of Mental Health) randomized 340 patients to Hypericum, sertraline, or placebo for 8 weeks, whereas the Massachusetts General Hospital study randomized 135 patients to Hypericum, fluoxetine, or placebo for 12 weeks. The investigators examined whether remission was associated with early changes in anxiety/somatization symptoms. In the National Institute of Mental Health study, significant associations were observed between remission and early improvement in the anxiety (psychic) item (sertraline arm), somatic (gastrointestinal item; Hypericum arm), and somatic (general) symptoms (placebo arm). None of the three treatment arms of the Massachusetts General Hospital study showed significant associations between anxiety/somatization symptoms and remission. When both study samples were pooled, we found associations for anxiety (psychic; selective serotonin reuptake inhibitors arm), somatic (gastrointestinal), and hypochondriasis (Hypericum arm), and anxiety (psychic) and somatic (general) symptoms (placebo arm). In the entire sample, remission was associated with the improvement in the anxiety (psychic), somatic (gastrointestinal), and somatic (general) items. The number and the type of anxiety/somatization items associated with remission varied depending on the intervention. Early scrutiny of the Hamilton Depression Rating Scale-17 anxiety/somatization items may help to predict remission of major depressive disorder.

Download full-text


Available from: David Mischoulon, Mar 30, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Generalized anxiety disorder (GAD) is often presented with major depression (MD). GAD-MD can be a chronic and disabling condition, and patients suffering from this disorder often respond poorly to psychopharmacological treatment and experience side effects with medication. Therefore, there is a high demand for effective nonpharmacological therapy for GAD-MD patients. The current study explores the use of a radioelectric asymmetric conveyer (REAC) device in the treatment of GAD-MD. Participants were 24 patients diagnosed with GAD-MD being treated at a public psychiatric center. All patients were dissatisfied with their current pharmacological treatment. Patients were evaluated using the 21-item Hamilton Depression (HAM-D) rating scale and the Symptom Check List-90-Revised (SCL-90R) before and after REAC brain stimulation treatment cycles. After REAC brain stimulation treatment, all patients experienced a significant reduction in anxiety and depression. These results were confirmed by physician examination, HAM-D scores, and SCL-90R total scores. These results indicate a role for REAC brain stimulation in the management of psychiatric conditions, specifically, GAD-MD comorbidity. REAC treatments are synergistic to drug therapy and appear to be helpful in reducing the side effects of medication. Future studies should evaluate the long-term effects of REAC treatment.
    Neuropsychiatric Disease and Treatment 08/2011; 7(1):449-55. DOI:10.2147/NDT.S23420 · 1.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To evaluate the efficacy and safety of Kaiyuning tablets for the treatment of mild to moderate depressive disorders. Methods: This is a multi-center, randomized, double-blind, double-dummy, and controlled study. Totally 228 patients were enrolled. The subjects were randomly assigned to Kaiyuning group (n=114) or fluoxetine group (n=114), and treated for six weeks. The efficacy was evaluated with Hamilton Depression Scale (HAMD), Hamilton Anxiety Scale (HAMA) and Clinical Global Impression Scale (CGI). The safety and tolerability were assessed with the incidence of adverse events, hematology, clinical chemistry, urinalysis, electrocardiogram and vital sign. Results: Finally 113 patients in Kaiyuning group and 111 patients in fluoxetine group included in the statistical analysis of the effect. The HAMD score (12.7±3.7) in Kaiyuning group reduced more than that (11.0±4.6) in fluoxetine group in ITT population (F=5.36, P=0.022). In PP population, the difference showed no significance (F=2.06, P=0.153). The response rate was 81.4% (92/113) in Kaiyuning group and 70.3% (78/111) in fluoxetine group, the difference showed no significance (P>0.05). Incidence of the adverse events related to drugs were similar between the two group. The major adverse events was nausea (1.8%). Conclusions: Kaiyuning tablets is a safe and effective antidepressant. ©, 2015, Chinese Journal of New Drugs Co. Ltd. All right reserved.
    Chinese Journal of New Drugs 07/2015; 24(13):1504-1508.